Lunai Bioworks Inc. (LNAI)Healthcare | Biotechnology | Los Angeles, United States | NasdaqCM
2.83 USD
-0.11
(-3.742%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:13 a.m. EDT
Lunai Bioworks presents a catastrophic long-term investment case driven by a complete lack of profitability and a deteriorating balance sheet. The company is burning massive amounts of cash with negative free cash flow and operating margins of nearly -68%, while holding negligible assets against significant debt. The stock has suffered a brutal multi-year decline, dropping over 93% from its historical highs, reflecting the market's verdict on its unsustainable business model. While recent headlines about defense contracts and a reverse split suggest a desperate attempt to engineer a turnaround or manipulate share price, the fundamentals remain broken with no path to positive earnings in sight. The recent price spike appears to be purely speculative volatility chasing rather than a genuine recovery in business quality. For investors, this is a clear 'avoid' signal; the company is effectively a shell of a biotech firm with no proven track record of success and a precarious financial structure. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.154799 |
| AutoARIMA | 0.156080 |
| AutoTheta | 0.159742 |
| AutoETS | 0.159765 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 10.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.505 |
| Excess Kurtosis | -0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.008 |
| Market Cap | 12,830,908 |
| Beta | 0.35 |
| Previous Name | Enochian Biosciences, Inc. |
| Website | https://www.lunaibioworks.com |
As of July 11, 2026, 4:13 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by significant open interest in out-of-the-money puts relative to calls. The put volume is concentrated at the money, suggesting a fear of a drop to or below current levels rather than a crash. Conversely, call activity is sparse and dominated by deep in-the-money positions, indicating minimal speculative appetite for further upside despite recent volatility spikes.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.87411034 |
| Address1 | 2,080 Century Park East |
| Address2 | Suite 906 |
| All Time High | 1,102.4 |
| All Time Low | 1.208 |
| Ask | 3.54 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 66,430 |
| Average Daily Volume3 Month | 1,270,760 |
| Average Volume | 1,270,760 |
| Average Volume10Days | 66,430 |
| Beta | 0.353 |
| Bid | 2.05 |
| Bid Size | 2 |
| Book Value | -2.136 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.83 |
| Current Ratio | 0.194 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.945 |
| Day Low | 2.71 |
| Display Name | Lunai Bioworks |
| Earnings Timestamp End | 1,778,875,200 |
| Earnings Timestamp Start | 1,778,875,200 |
| Ebitda | -9,769,810 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.135 |
| Enterprise To Revenue | 529.415 |
| Enterprise Value | 11,087,004 |
| Eps Trailing Twelve Months | -61.52 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.77866 |
| Fifty Day Average Change | 0.051339865 |
| Fifty Day Average Change Percent | 0.018476482 |
| Fifty Two Week Change Percent | -87.41103 |
| Fifty Two Week High | 28.8 |
| Fifty Two Week High Change | -25.97 |
| Fifty Two Week High Change Percent | -0.90173614 |
| Fifty Two Week Low | 1.208 |
| Fifty Two Week Low Change | 1.622 |
| Fifty Two Week Low Change Percent | 1.3427153 |
| Fifty Two Week Range | 1.208 - 28.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,518,013,800,000 |
| Float Shares | 3,348,686 |
| Free Cashflow | -6,964,201 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 20,942 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31304002 |
| Held Percent Institutions | 0.027590001 |
| Implied Shares Outstanding | 4,533,890 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,779,408,000 |
| Last Split Factor | 1:8 |
| Long Business Summary | Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California. |
| Long Name | Lunai Bioworks Inc. |
| Market | us_market |
| Market Cap | 12,830,908 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_549849556 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-14 |
| Net Income To Common | -128,284,016 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 12,569,303 |
| Open | 2.94 |
| Operating Cashflow | -5,258,315 |
| Operating Margins | -68.152985 |
| Payout Ratio | 0.0 |
| Phone | 305 918 1980 |
| Pre Market Change | -0.07489991 |
| Pre Market Change Percent | -2.64664 |
| Pre Market Price | 2.7551 |
| Pre Market Time | 1,784,029,627 |
| Prev Name | Enochian Biosciences, Inc. |
| Previous Close | 2.94 |
| Price Hint | 4 |
| Price To Book | -1.3249063 |
| Price To Sales Trailing12 Months | 612.6878 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.164 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.11 |
| Regular Market Change Percent | -3.7415 |
| Regular Market Day High | 2.945 |
| Regular Market Day Low | 2.71 |
| Regular Market Day Range | 2.71 - 2.945 |
| Regular Market Open | 2.94 |
| Regular Market Previous Close | 2.94 |
| Regular Market Price | 2.83 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 36,940 |
| Return On Assets | -0.096470006 |
| Return On Equity | -3.25456 |
| Revenue Per Share | 0.008 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,533,890 |
| Shares Percent Shares Out | 0.033099998 |
| Shares Short | 150,195 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 345,109 |
| Short Name | Lunai Bioworks Inc. |
| Short Percent Of Float | 0.038 |
| Short Ratio | 0.06 |
| Source Interval | 15 |
| State | CA |
| Symbol | LNAI |
| Total Cash | 3,155,272 |
| Total Cash Per Share | 0.696 |
| Total Debt | 1,411,367 |
| Total Revenue | 20,942 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -61.52 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.627825 |
| Two Hundred Day Average Change | -2.7978249 |
| Two Hundred Day Average Change Percent | -0.49714142 |
| Type Disp | Equity |
| Volume | 36,940 |
| Website | https://www.lunaibioworks.com |
| Zip | 90,067 |